Development of a real‐time RT‐PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia
暂无分享,去创建一个
[1] S. Fröhling,et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.
[2] A. Borkhardt,et al. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy‐related AML after treatment without etoposides , 2003, Genes, chromosomes & cancer.
[3] D. Grimwade,et al. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia , 2002, Leukemia.
[4] M. Breuning,et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB‐MYH11 gene fusion , 2002, British journal of haematology.
[5] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[6] D. Cilloni,et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts , 2002, Leukemia.
[7] S. Fröhling,et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Baccarani,et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. , 2002, Blood.
[9] T. Naoe,et al. Rapid Screening of Leukemia Fusion Transcripts in Acute Leukemia by Real-time PCR , 2002, Leukemia & lymphoma.
[10] M. Caligiuri,et al. Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia , 2001, Leukemia.
[11] C. Bloomfield,et al. Clinical importance of cytogenetics in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.
[12] M. Caligiuri,et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. , 2001, Leukemia.
[13] B. Roe,et al. DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis. , 2000, Human molecular genetics.
[14] M. Vidaud,et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR , 2000, Leukemia.
[15] A. Ganser,et al. Real‐time RT‐PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)‐positive AML patients , 1999, British journal of haematology.
[16] U. Jaeger,et al. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR , 1999, Leukemia.
[17] J. Rowley. The role of chromosome translocations in leukemogenesis. , 1999, Seminars in hematology.
[18] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[19] U. Jaeger,et al. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Roe,et al. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia. , 1997, Genes, chromosomes & cancer.
[21] E. Macintyre,et al. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. , 1996, Blood.
[22] J. Rowley,et al. Abnormalities of Chromosome Band 11q23 and the MLL Gene in Pediatric Myelomonocytic and Monoblastic Leukemias: Identification of the t(9;11) as an Indicator of Long Survival , 1995, Journal of pediatric hematology/oncology.
[23] M. Seto,et al. A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemias with 11q23 abnormalities. , 1994, Blood.
[24] M. Seto,et al. MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. , 1993, Oncogene.
[25] J. Rowley,et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. , 1993, The New England journal of medicine.
[26] P. Nowell,et al. Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. , 1993, Proceedings of the National Academy of Sciences of the United States of America.